Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Total Non-Current Liabilities: 2019-2025

Historic Total Non-Current Liabilities for Allogene Therapeutics (ALLO) over the last 7 years, with Sep 2025 value amounting to $109.0 million.

  • Allogene Therapeutics' Total Non-Current Liabilities fell 7.42% to $109.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $109.0 million, marking a year-over-year decrease of 7.42%. This contributed to the annual value of $118.8 million for FY2024, which is 5.31% down from last year.
  • As of Q3 2025, Allogene Therapeutics' Total Non-Current Liabilities stood at $109.0 million, which was down 1.76% from $110.9 million recorded in Q2 2025.
  • Allogene Therapeutics' Total Non-Current Liabilities' 5-year high stood at $152.9 million during Q1 2023, with a 5-year trough of $97.2 million in Q2 2021.
  • For the 3-year period, Allogene Therapeutics' Total Non-Current Liabilities averaged around $124.0 million, with its median value being $119.8 million (2024).
  • In the last 5 years, Allogene Therapeutics' Total Non-Current Liabilities surged by 46.50% in 2022 and then dropped by 21.65% in 2024.
  • Over the past 5 years, Allogene Therapeutics' Total Non-Current Liabilities (Quarterly) stood at $117.8 million in 2021, then increased by 26.32% to $148.8 million in 2022, then decreased by 15.74% to $125.4 million in 2023, then fell by 5.31% to $118.8 million in 2024, then dropped by 7.42% to $109.0 million in 2025.
  • Its last three reported values are $109.0 million in Q3 2025, $110.9 million for Q2 2025, and $111.3 million during Q1 2025.